Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Remdesivir Plus Baricitinib	516
Overall Study	STARTED	Remdesivir Plus Dexamethasone	494
Overall Study	Treated	Remdesivir Plus Baricitinib	503
Overall Study	Treated	Remdesivir Plus Dexamethasone	482
Overall Study	ITT and Modified ITT Population	Remdesivir Plus Baricitinib	516
Overall Study	ITT and Modified ITT Population	Remdesivir Plus Dexamethasone	494
Overall Study	As Treated Population	Remdesivir Plus Baricitinib	503
Overall Study	As Treated Population	Remdesivir Plus Dexamethasone	482
Overall Study	COMPLETED	Remdesivir Plus Baricitinib	495
Overall Study	COMPLETED	Remdesivir Plus Dexamethasone	475
Overall Study	NOT COMPLETED	Remdesivir Plus Baricitinib	21
Overall Study	NOT COMPLETED	Remdesivir Plus Dexamethasone	19

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04640168/flow